Chinook Therapeutics, Inc. (KDNY) — Financial statements
Income statement, balance sheet, and cash flow for Chinook Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 6↓88.1% | 52↑6142.4% | 0.83↓95.2% | 17↑14.4% | 15 | |
| Cost of Revenue | 2↑2.1% | 2↑299.8% | 0.42↓23.8% | 0.55↓5.1% | 0.58 | |
| Gross Profit | 4↓91.2% | 50↑12230.4% | 0.41↓97.6% | 17↑15.2% | 15 | |
| Operating Expenses | ||||||
| R&D Expenses | 141↑45.6% | 97↑169.0% | 36↑111.9% | 17↓77.6% | 76 | |
| General & Administrative Expenses | 36↑13.8% | 32↑67.3% | 19↑545.2% | 3↓91.8% | 36 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 36↑13.8% | 32↑67.3% | 19↑545.2% | 3↓91.8% | 36 | |
| Other Expenses | 2↑2.1% | 2↑299.8% | 0.42↑41.1% | 0.30↓92.5% | 4 | |
| Operating Expenses | 179↑37.3% | 131↑135.1% | 56↑178.2% | 20↓82.8% | 116 | |
| Total Costs & Expenses | 179↑37.3% | 131↑135.1% | 56↑178.2% | 20↓82.9% | 116 | |
| Operating Results | ||||||
| Operating Income | -185↓86.9% | -99↓76.1% | -56↓181.6% | -20↑80.3% | -101 | |
| Depreciation & Amortization | 21↓50.1% | 42↑1764.9% | 2↑331.7% | 0.52↓89.5% | 5 | |
| EBITDA | -164↓187.2% | -57↓5.9% | -54↓177.6% | -19↑80.8% | -101 | |
| EBIT | -173↓74.8% | -99↓18.5% | -84↓473.7% | -15 | 0.00 | |
| Interest & Other Income | ||||||
| Net Interest Income | -7 | 0.00↑100.0% | -0.02↑54.5% | -0.03 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 7 | 0.00↓100.0% | 0.02↓54.5% | 0.03 | 0.00 | |
| Non-Operating Income | -12 | 0.00↓100.0% | 27↑607.9% | -5 | 0.00 | |
| Other Income / Expenses | 5↑2928.8% | -0.17↑99.4% | -27↑57.7% | -65↓1341.7% | 5 | |
| Income Before Tax | -180↓81.7% | -99↓18.6% | -84↓79.8% | -47↑51.6% | -96 | |
| Income Tax Expense | 4↑107.4% | 2↑204.5% | -2↓703.3% | 0.33↑142.4% | -0.78 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -185↓82.2% | -101↓24.1% | -82↓74.2% | -47↑50.9% | -95 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -185↓82.2% | -101↓24.1% | -82↓74.2% | -47↑50.9% | -95 | |
| Bottom-Line Net Income | -185↓82.2% | -101↓24.1% | -82↓74.2% | -47↑50.9% | -95 | |
| EPS (Basic) | -2.87↓29.3% | -2.22↑64.2% | -6.20↓458.6% | -1.11↓92400.0% | -0.00 | |
| EPS (Diluted) | -2.87↓29.3% | -2.22↑64.2% | -6.20↓458.6% | -1.11↓92400.0% | -0.00 | |
| Weighted Average Shares | 64↑41.1% | 46↑246.3% | 13↓68.8% | 42↓99.9% | 78,812 | |
| Weighted Average Diluted Shares | 64↑41.1% | 46↑246.3% | 13↓68.8% | 42↓99.9% | 78,812 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.